MedTrace Logo

Single and Repeat Doses of DMT in Healthy Subjects

NCT05559931 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-01-28

No results posted yet for this study

Summary

This study aims to assess the safety and tolerability of single ascending, and fixed repeated doses of N,N-Dimethyltryptamine (DMT) in healthy subjects, when given by intravenous (IV) infusion.

Conditions

Interventions

DRUG

N,N-Dimethyltryptamine

IV infusion over 6 hours

DRUG

Placebo

Placebo infusion over 6 hours

Sponsors & Collaborators

  • Centre for Human Drug Research, Netherlands

    collaborator OTHER

  • Algernon Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Gabriel Jacobs, MD, PhD · Centre for Human Drugs Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-13
Primary Completion
2026-03-31
Completion
2026-03-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05559931 on ClinicalTrials.gov